PhaseBio Pharmaceuticals, Inc.
4020 Aerial Center Parkway
Suite 101
Morrisville
North Carolina
27560
United States
Tel: 919-535-8861
Fax: 919-535-8867
Website: http://www.phasebio.com/
106 articles about PhaseBio Pharmaceuticals, Inc.
-
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
-
PhaseBio Secures $34 Million in Series D Financing
9/10/2018
Proceeds will advance clinical development of PB2452, a potentially first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH
-
PhaseBio Announces $15.6M in Funds to Support Clinical Advancement of Orphan Cardiovascular Pipeline
11/29/2017
PhaseBio entered into a $7.5 million term loan facility with Silicon Valley Bank, subject to funding in up to three tranches.
-
PhaseBio Enters Worldwide License Agreement With MedImmune for a Reversal Agent for Ticagrelor
11/28/2017
Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.
-
PhaseBio Announces Leadership Team Appointments
4/7/2016
-
PhaseBio Receives FDA Orphan Drug Designation For Vasomera (PB1046) For The Treatment Of Cardiomyopathy Associated With Dystrophinopathies
12/1/2015
-
PhaseBio Announces Initiation Of Phase IIa Multiple Ascending Dose Study Of Once-Weekly Basal Insulin PE0139 In Type 2 Diabetes
11/9/2015
-
PhaseBio To Present At Rodman & Renshaw 17th Annual Global Investment Conference
9/3/2015
-
PhaseBio Announces Positive Data For Type 2 Diabetes Treatments PE0139 And PB1023
6/8/2015
-
PhaseBio To Present At The American Diabetes Association 75th Scientific Sessions
6/2/2015
-
PhaseBio Announces Promising Pre-Clinical Results For PB1046 In Models Of Duchenne Muscular Dystrophy
4/22/2015
-
AstraZeneca PLC-Backed PhaseBio Locks in $40 Million
3/12/2015
-
PhaseBio Pharmaceuticals, Inc. Announces Expansion Of Leadership Team
3/3/2015
-
PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases
6/18/2013
-
PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes
6/4/2013
-
PhaseBio Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/29/2013
-
PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer
12/4/2012
-
PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes
8/21/2012
-
PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio
6/5/2012
-
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease
2/22/2012